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Peripheral nerve injury can occur as a result of trauma or disease and carries
significant morbidity including sensory and motor loss. The body has limited
ability for nerve regeneration and functional recovery. Left untreated, nerve
lesions can cause lifelong disability. Traditional treatment options such as
neurorrhaphy and neurolysis have high failure rates. Surgical reconstruction
with autograft carries donor site morbidity and often provide suboptimal results.
Mesenchymal stem cells (MSCs) are known to have promising regenerative
potential and have gained attention as a treatment option for nerve lesions. It is
however, unclear whether it can be effectively used for nerve regeneration.
AIM
To evaluate the evidence for the use of human umbilical cord derived MSCs
(UCMSCs) in peripheral nerve regeneration.
METHODS
We carried out a systematic literature review in accordance with the PRISMA
protocol. A literature search was performed from conception to September 2019
using PubMed, EMBASE and Web of Science. The results of eligible studies were
appraised. A risk of bias analysis was carried out using Cochrane’s RoB 2.0 tool.
RESULTS
Fourteen studies were included in this review. A total of 279 subjects, including
both human and animal were treated with UCMSCs. Four studies obtained
UCMSCs from a third-party source and the remainder were harvested by the
investigators. Out of the 14 studies, thirteen conducted xenogenic transplantation
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into nerve injury models. All studies reported significant improvement in nerve
regeneration in the UCMSC treated groups compared with the various different
controls and untreated groups.
CONCLUSION
The evidence summarised in this PRISMA systematic review of in vivo studies
supports the notion that human UCMSC transplantation is an effective treatment
option for peripheral nerve injury.
Key words: Umbilical cord; Mesenchymal stem cells; Transplantation; Peripheral nerve
regeneration
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: While human umbilical cord derived mesenchymal stem cells hold promise as a
treatment option for peripheral nerve lesions, robust in vivo models are required in order
to determine the best method of delivering mesenchymal stem cells to sites of injury.
Citation: Bojanic C, To K, Zhang B, Mak C, Khan WS. Human umbilical cord derived





Peripheral nerve injuries can occur as a result of trauma or disease and can lead to
significant morbidity including sensory loss, motor loss and chronic pain[1]. These
injuries cause life-long disability in up to 2.8% of all trauma patients[2]. Damage to
peripheral  nerves  most  commonly occurs  as  a  result  of  laceration,  compression,
ischaemia or traction[1]. As classified by Seddon in 1943, nerve injury can range from
focal  demyelination  termed  neurapraxia,  to  total  nerve  transection  termed
neurotmesis[3,4]. The mechanism of recovery post-injury occurs by either branching of
collateral  axons  or  by  regeneration  of  the  damaged neuron[4,5].  In  order  for  full
neuronal recovery to occur, Wallerian degeneration, axonal regeneration and end-
organ  reinnervation  must  take  place.  This  is  driven  by  an  array  of  neurotropic
factors[4]. However, recovery in function following peripheral nerve injury is hindered
by  complex  pathological  mechanisms  such  as  poor  nerve  regeneration,
neuromuscular atrophy, and end-plate degeneration which can lead to suboptimal
neuron function[6-9].
Traditionally, peripheral nerve injury can be managed conservatively or surgically
with neurolysis, neural suturing, end-to-side neurorrhaphy and nerve autograft[10-12].
Even with optimum surgical repair,  most methods will  attain partial but not full
return of nerve function[10]. Certain peripheral nerve injuries, such as severe brachial
plexus  or  long  traction  injuries  remain  inoperable[10].  Autografts  have  several
disadvantages,  including donor site morbidity,  mismatch in nerve and graft  size
resulting  in  poor  engraftment,  and  the  potential  for  development  of  painful
neuromas[11,13,14].  Alternative methods of treating peripheral nerve injuries may be
through cell-based regenerative therapies[15].
Transplantation  of  mesenchymal  stem  cells  (MSCs),  given  their  regenerative
properties  and highly  proliferative  capacity,  has  been proposed as  a  promising
therapeutic option for peripheral nerve regeneration[16,17]. MSCs are plastic-adherent,
undifferentiated, multipotent cells that can be harvested from numerous sites of the
body  including  bone  marrow,  adipose  tissue,  dental  pulp,  amniotic  fluid  and
umbilical cord[17-19].  MSCs from different tissue origins can have distinct cytokine
expression profiles, and thus may enable different MSCs to be particularly suited to
certain  clinical  applications[20,21].  Owing  to  low  immunogenicity,  MSCs  may  be
transplanted allogenically with minimal consequence[22]. The particular mechanisms
through which MSCs aid nerve repair have not yet been fully characterised. MSCs
from various sources such as adipose tissue and bone marrow are able to differentiate
into Schwann cells[23,24]. While some in vitro experiments suggest that transplanted
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MSCs may be stimulated by peripheral nerves to differentiate into Schwann cells[25],
alternative  findings  have  instead  shown  that  transplanted  MSCs  encourage
endogenous cells  to  express  regenerative  phenotypes[26].  Increasingly,  MCSs are
believed to mediate their regenerative properties predominantly through paracrine
effects [27 ,28].  Aside  from  acting  through  soluble  factors [29],  MSCs  have  also
demonstrated  the  ability  to  secrete  extracellular  vesicles  that  contain  bioactive
components such as miRNA and cytokines[30]. Indeed, native Schwann cells have been
shown  to  facilitate  axonal  regeneration  following  injury  through  secretion  of
exosomes that decrease GTPase RhoA activity[31]. Similarly, human MSCs may act to
achieve the same result through exosomes by upregulation of the PI3 kinase and Akt
signalling cascades[32].
MSCs from umbilical cord are convenient to harvest from post-natal tissue in a
non-invasive manner and possess a high capacity to expand ex vivo[33]. They express
low levels of HLA-DR compared to MSCs from other cell sources and therefore pose
low  risk  of  immunogenic  complications  following  allogenic  transplantation[34].
Through  sequential  treatment  with  β-mercaptoethanol  and  various  cytokines,
umbilical cord derived MSCs (UCMSCs) can adopt a Schwann-like phenotype[35]. In
addition, UCMSCs have been shown to possess greater paracrine effects than those of
bone marrow-derived MSCs (BMMSC) and adipose-derived MSCs[17,29], and are able to
potentiate axonal regeneration and peripheral nerve functional regeneration through
these effects[11,17,29,36]. UCMSCs have been proposed to exert neuroprotective effects
through secretion of Brain Derived Neurotrophic Factor (BDNF)[37], angiopoietin-2
and  CXCL-16[38,39].  Other  studies  have  suggested  that  they  indirectly  promote
neurogenesis[40,41].  UCMSCs  are  also  able  to  indirectly  enhance  expression  of
neurotransmitters such as BDNF and neurotrophin-3 (NTF3) which are postulated to
aid neuro-regeneration[42,43].
To date, there have been over 400 clinical trials that explore the use of MSCs in
transplantation; UCMSCs follow BMMSCs as the second most commonly used cell
source[44]. In this PRISMA systematic review, we analyse the evidence for the use of
human UCMSCs in peripheral nerve regeneration by examining in vivo studies.
MATERIALS AND METHODS
A literature search was performed from conception to September 2019 using PubMed,
EMBASE  and  Web  of  Science.  The  following  search  terms  were  used:
((((((((Mesenchymal stem cells) OR mesenchymal stem cell) OR MSC) OR MSCs) OR
Mesenchymal stromal cell) OR Mesenchymal cell)) AND (((((Nerve) OR Peripheral
nerve)  OR Peripheral  nerve injury)  OR damaged nerve)  OR nerve injury))  AND
((((((repair) OR regeneration) OR regrowth) OR regenerate) OR renew) OR restore).
We adhered to the recommendations as stipulated by the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[45].
We included case series, case control, cohort studies and randomised controlled
trials. We enrolled studies that examined peripheral nerve lesions treated with human
UCMSCs in in vivo human and animal subjects. Studies that only conducted in vitro
experiments  were  excluded.  Studies  that  investigated  central  nervous  system
regeneration using UCMSCs were excluded. All included studies were published in
the English language. We excluded all unpublished and retracted literature.
CB and KT carried out the search independently. RoB2 tool was used by CM and
BZ to assess the risk of bias in the studies, all discrepancy in results were resolved by
discussion.
RESULTS
A total of 210 studies were screened for title, abstract and the inclusion/exclusion
criteria were applied (Figure 1). One retracted study was excluded. Fourteen studies
were reviewed in full  text.  The overall  bias  of  studies is  shown in Figure 2.  The
summary of results is shown in Figure 3. All 14 studies were of a case control design
(Table  1).  Four  studies  obtained  UCMSCs  from  a  third-party  source  and  the
remainder were harvested directly from human subjects. Out of the 14 studies, ten
involved xenogenic transplantation into sciatic nerve injury specimens that were
either crushed or transected. The studies were grouped according to Seddon’s seminal
nerve injury classification system, which includes axonotmesis (injury to nerve sheath
alone) and neurotmesis (injury to the entire nerve)[3].  A total of 279 subjects were
treated with UCMSCs.  All  studies  reported significant  improvement  in  UCMSC
treated groups compared with the various different controls and untreated groups.
WJSC https://www.wjgnet.com April 26, 2020 Volume 12 Issue 4
Bojanic C et al. UCMSCs in nerve regeneration
290
The studies did not report any significant complications.
UCMSCs in peripheral nerve axonotmesis
Four studies that included a total of 90 treated subjects assessed the use of UCMSCs in
peripheral nerve axonotmesis models of sciatic nerve crush injury (Table 1). All four
studies harvested UCMSCs from human subjects and transplanted the UCMSCs into
murine subjects. The methods of UCMSC delivery to the crush injury varied among
studies.
Studies, by Sung et al[46] (2012) and Hei et al[47] (2016) examined the effect of direct
intralesional UCMSC injections on murine subjects with sciatic nerve crush injuries.
Both studies monitored subjects up to 4 wk post-intervention. Sung et al[46]  (2012)
found that expression of brain-derived neurotrophic factor (BDNF) and tyrosine
kinase receptor B mRNA increased at 4 wk following UCMSC injection. Functional
recovery was measured in terms of the sciatic function index (SFI), which showed a
dramatic improvement at 4 wk in UCMSC treated groups compared to untreated
groups. Retrograde axonal transport was estimated through fluoro Gold-labelled
neuron counts  and the  UCMSC group was  found to  have  a  significantly  higher
neuron count. It was found that axon density was significantly greater in the UCMSC
group. Hei et al[47] (2016) transfected UCMSCs with a BDNF-adenovirus vector. The
authors  found  that  both  UCMSC  and  BDNF-UCMSC  groups  had  significant
improvements  in SFI,  axon count and axon density at  4  wk after  treatment.  The
BDNF-UCMSC group displayed increased peripheral nerve regeneration compared
with UCMSC alone.
Gartner et al[48,49] conducted two studies published in the same year. In one study,
Chitosan type III membrane was used to aid UCMSC infiltration in murine sciatic
crush models[48]. The authors evaluated motor and sensory functional recovery up to
12 wk following transplantation with and without Chitosan type III wrapping. Both
treatment groups showed improvement in SFI, extensor postural thrust (EPT) and
withdrawal reflex latency (WRL). The control group with Chitosan type III membrane
alone showed a significant improvement in post-traumatic axonal regrowth compared
to the untreated control group. In a separate study, the same group examined the
effect of using poly (DL-lactide-e-caprolactone) (PLC) membranes to deliver UCMSCs
into sciatic nerve crush injuries[49].  Peripheral nerve regeneration was assessed in
terms of SFI, EPT, and WRL at 12 wk. Undifferentiated and differentiated UCMSCs
were used in different groups. Both groups showed an increase in myelin sheath
thickness compared to control groups. The SFI was severely affected at week-2 post-
crush injury in all experimental groups and improved gradually up to week 12 when
values were indistinguishable from controls.
Studies of UCMSCs in peripheral nerve neurotmesis
Nine  of  the  fourteen  studies  assessed  the  use  of  UCMSCs  in  peripheral  nerve
neurotmesis models (Table 2). All nine were case control studies. Five studies had
murine subjects, two had rabbit subjects, one had canine subjects, and one had human
subjects.  Six  studies  transplanted UCMSCs into  a  sciatic  nerve  gap model.  Two
studies transplanted UCMSCs into tibial nerve and recurrent laryngeal nerve crush
models. One study conducted allogenic transplantation in humans. A total of 151
subjects were treated. Methods of MSC delivery and transplantation varied among
studies.
Several groups sought to improve nerve regeneration with UCMSCs combined
with longitudinal scaffolds. Zarbakhsh et al[11] (2015) loaded UCMSCs on a silicone
tube and interposed it into a murine sciatic nerve gap model. The authors attempted
to  compare  the  histological  outcomes  of  human  UCMSCs  and  rat  BMMSCs  in
regenerating sciatic nerve gap in rats. While the author showed favourable results in
nerve regeneration for both UCMSCs and BMMSC, the latter was found to produce
superior results at the end point of 12 wk. The BMMSC group showed greater axon
number and thicker myelin sheath diameter than the UCMSC group.
Ma et al[17] (2019) injected UCMSC-derived extracellular vesicles (EVs) into the tail
veins of rats and sutured a silicone rubber tube into the sciatic nerve gaps of 24 rats.
The  authors  found  that  UCMSC-EVs  promoted  motor  function  recovery  and
regeneration of axons and attenuated muscle atrophy. SFI analysis was used to assess
the functional improvements. At 8 wk, UCMSC-EV group had similar SFI values to
normal rats.
Matsuse et al[35] (2010) combined UCMSCs and Matrigel into transpermeable tubes
and transplanted it into transected murine sciatic nerve tissue specimens. The authors
induced  UCMSCs  into  cells  with  Schwann  cell  properties  by  using  β-
mercaptoethanol, all-trans-retinoic acid and various cytokines. Subsequently, Matsuse
et al[35] examined the effect of these induced UCMSCs and used two control groups; a
positive control of human Schwann cells and a negative control of Matrigel alone. The
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Table 1  Studies of umbilical cord derived mesenchymal stem cells in peripheral nerve axonotmesis and diabetic neuropathy in vivo
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UCMSCs: Umbilical cord derived mesenchymal stem cells; BDNF: Brain-derived neurotrophic factor; SFI: Sciatic function index; PBS: Phosphate buffered
saline; PLC: Poly (DL-lactide-ε-caprolactone); WRL: Withdrawal reflex latency; EPT: Extensor postural thrust.
group  assessed  SFI  values  and  compared  immunoelectron  micrographs.  They
concluded  that  the  treatment  group  with  Schwann  Cell-UCMSCs  group  was
equivalent  to  treatment  with  Schwann  cells  based  on  histological  criteria  and
functional recovery.
Cui  et  al[14]  (2018)  and  Pan  et  al[50]  (2017)  delivered  UCMSCs  using  a  collagen
conduit. Cui et al[14] (2018) transplanted human UCMSCs into canine sciatic nerve gap
models via a longitudinally orientated collagen conduit embedded with UCMSCs.
Compound muscle action potential (CMAP) was found to be statistically greater in
the UCMSC treated group compared with the collagen conduit only group. Pan et al[50]
(2017)  appraised  the  use  of  UCMSCs  with  a  heparinised  collagen  conduits  in
transected rabbit recurrent laryngeal nerves. The authors assessed the effectiveness of
passage-4 UCMSCs loaded on heparinised scaffold that released Nerve growth factor
(NGF). Electromyograms at 8 wk revealed that treated lesions recovered normal nerve
function. Biological markers of neurogenesis, including calcium-binding protein S100,
neurofilament and AChE, were expressed at a greater level following treatment. Xiao
et al[51] (2015) undertook a study exploring the effect of UCMSCs in a chitosan conduit
interposed into  the  tibial  nerve  of  a  rabbit  model.  Xiao et  al[51]  found that  nerve
conduction velocity was significantly higher in the treatment group. The myelin
sheath thickness and the growth of axis bud were both increased in the UCMSC
group. Pereira et al[52]  (2014) used PLC as a conduit for UCMSCs in murine sciatic
nerve  crush  models.  The  group  compared  differentiated  and  undifferentiated
UCMSCs. They established no difference in the degree of nerve regeneration between
UCMSC that  were differentiated into neural-glial-like cells  and undifferentiated
UCMSC groups. Both UCMSC groups showed increased myelin sheath thickness and
enhanced recovery in motor and sensory function.
Two groups sought to investigate the use of  UCMSCs embedded on a human
amniotic membrane scaffold[5,53]. Li et al[53] (2012) found significant improvements in
SFI, CMAP and gastrocnemius muscle diameter in UCMSC-loaded scaffolds group
compared to cell-free scaffolds. Li et al[6] (2013) analysed how UCMSCs loaded on a
human amniotic membrane scaffold affected the repair of a transected radial nerve in
human subjects.  Thirty-two patients  with radial  nerve injuries  from radial  shaft
fractures were included in the study; twelve patients received neurolysis to remove
neural scar tissue, and transplantation of UCMSCs on an amniotic membrane. The
remainder 18 patients received neurolysis only. At 12 wk, the electrophysiological
function of the UCMSC-treated group had improved electromyography readings. The
muscular power, touch sensation and pain sensation were also significantly improved
as compared to the neurolysis group.
Studies of UCMSCs in diabetic neuropathy
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Figure 1
Figure 1  PRISMA Flow diagram.
One study explored the role of UCMSCs in femoral nerve neuropathy[54] (Table 1). The
authors modelled diabetic neuropathy in murine subjects by inducing diabetes with
streptozotocin and created a dorsal hind foot ulcer through empyrosis. UCMSCs were
delivered intravascularly through the femoral artery in the treatment group. Saline
injections were used in the control group. Serum NGF and neurofilament 200 (NF-
200) were measured by Enzyme Linked Immunosorbent Assay (ELISA). The results
demonstrated that serum NGF and NF-200 increased in the UCMSC treated rats.
Additionally, functional studies using electroneurogram showed that femoral nerve
conduction was improved in the UCMSC subjects.
DISCUSSION
The studies  in this  review reported compelling positive outcomes for  the use of
human UCMSC to repair  peripheral  nerve lesions.  None of  the studies reported
immunogenic  nor  significant  complications.  While  the  source  cell  utilised  was
consistent among the studies, there were significant variability in cell treatment and
methods of  transplantation with variable effectiveness as determined by several
different outcome measures. There was also moderate heterogeneity in the in vivo
models used. It is therefore difficult to draw conclusions on the optimal method of cell
delivery to nerve lesions. Nevertheless, it does imply that UCMSCs are a useful cell
source.
The  process  of  cell  harvest  did  not  vary  greatly  between the  studies.  Human
umbilical cord and umbilical cord blood are generally considered medical waste and
so there are minimal ethical barriers to tissue sampling[55]. This provides a practical
advantage for the use of UCMSCs and may explain why it is commonly used in tissue
engineering experiments.  The biochemical properties of UCMSCs may also be of
advantage as studies comparing different source cells for MSCs have found UCMSCs
to possess a greater ability to proliferate ex vivo and express a higher level of Vascular
Endothelial  Growth  Factor  (VEG-F)  and  Human  Growth  Factor  (HGF)  at  late
passages[56,57].  One study in this review compared UCMSCs to BMMSCs in sciatic
nerve regeneration and found BMMSCs to produce superior results.  The authors
however,  evaluated cell  architecture  on microscopy but  did not  carry out  nerve
conduction  studies  or  functional  analysis  which  may  better  inform  clinical
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Figure 2
Figure 2  Summary of overall bias.
relevance[11].  UCMSCs also appear to have a different multilineage differentiation
profiles to other MSC, and is able to be induced into neuron-like cells in vitro, which
may favour applications in nerve regeneration[58]. There is some evidence to suggest
that characteristics of the donor affect the ability of UCMSCs to differentiate. For
example, undifferentiated UCMSCs obtained from patients with pre-eclampsia may
produce greater levels of neuronal markers[59].  Therefore, exploration of different
patient and gestational characteristics,  such as age could help determine optimal
source conditions.
There is no set protocol for the ex vivo expansion of UCMSCs in the literature. In
our article, UCMSCs were generally transplanted between the third and fifth passage.
Indeed, the gene expression profile of UCMSC is known to vary according to the
number of passages, with some studies showing that UCMSCs do not express CD105,
a defining marker for MSCs, until passage-5[60]. In view of this, it would be meaningful
to identify and investigate the expression of  important  neurogenic  markers  as  a
function of stages of passage in future experiments. Some of the studies in this review
pre-treated UCMSCs in order to induce them into particular cellular phenotypes prior
to transplantation. Pereira et al[52] and Gartner et al[49] utilised a similar culture protocol
and pre-treated UCMSCs with neurogenic media. They observed a neuroglial-like
morphology on microscopy and a transcriptomic profile showing upregulation of
neuroglial genes including Glial Fibrillary Acidic Protein (GFAP), Growth Associated
Protein 43 (GAP43) and Neuronal Specific Nuclear Protein (NeuN). Both studies
found differentiated MSCs to be more effective than undifferentiated UCMSCs. Aside
from gene expression, it would be important to clarify the exact mechanism through
which these  differentiated cells  act  to  promote  nerve  regeneration.  The optimal
protocol for differentiation is also ill-defined as Matsuse et al[35] used a different set of
culture condition to induce UCMSCs into Schwann-like cells and found the latter to
be more effective. Furthermore, there is a lack of agreement on the primary mode of
action of MSCs in promoting nerve regeneration. It is unclear whether transplanted
cells directly replicate and replace cells in the lesion. Some experiments of optic nerve
lesions suggest that transplanted MSCs remain local and replicate[61]. Emerging in vitro
evidence points towards paracrine effects as the predominant mechanism of action. It
appears  that  pre-treatment  of  Schwann  cells  with  UCMSC  conditioned  media
increases BDNF and NGF expression which are surrogate measures of neurogenic
potential[29]. In our review, Mak et al[17] examined the effectiveness of UCMSC-derived
exosomes in nerve repair. Through peripheral intravenous injection of UCMSC EVs,
they demonstrated that it could act systemically to encourage nerve regeneration at a
nerve gap without off-site complications. As the use of EVs in this endeavour gains
attention, further studies would be required to establish a dose-response relationship
and the best method for delivering EVs to lesions.
It is difficult to determine the best UCMSC implantation method. Our review has
captured studies  that  directly implanted UCMSCs and reported good outcomes.
Studies investigating the use of conduits to guide nerve regeneration suggest that this
is superior to direct implantation of MSCs alone[14,50]. The use of conduit that elude
growth  factors  such  as  NGF along  with  UCMSC implantation  appear  to  confer
additional  benefit[50].  Additionally,  intravenous  injection  of  UCMSC-EVs  at  a
peripheral site also produce positive outcomes[17]. Interestingly, a comparison of local
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Figure 3
Figure 3  Risk of bias in individual studies.
and intravenous BMMSC administration in sciatic nerve injury models suggest that
systemic treatment provides a more significant improvement in nerve conduction,
whereas local treatment improved neuronal fibre counts[62]. Other experiments have
shown that peripherally injected MSCs localise to nerve lesions in murine models of
sciatic nerve injury[63]. It could be inferred from these findings that there are differing
mechanisms and sites of action for the two methods of implantation, suggesting that a
treatment regime including both delivery methods concomitantly may produce the
best outcome.
There are several issues pertaining to translating the findings derived from in vivo
animal models for therapeutic application in humans. The majority of studies in our
review  employed  a  murine  surgical  sciatic  nerve  defect  model  to  assess  nerve
regeneration.  The  critical  nerve  gap  length,  defined  as  a  gap  across  which
regeneration would not occur without nerve grafting or bridging is considered to be
greater in humans than murine subjects[64,65].  Therefore,  studies assessing murine
nerve gaps may overestimate the therapeutic potential of treatments. Furthermore, it
may be difficult  to scale-up effective concentrations of  transplanted UCMSCs to
humans. In a study of rat nerve defects treated with tacrolimus, functional recovery
tapers off at 9 wk following treatment and becomes indistinguishable from untreated
rats at 10 wk[66]. Therefore, at later time points, which are more relevant to clinical
presentations of nerve injury, the regenerative biology of murine nerve appears to
differ from that of humans. Our interpretation from the in vivo animal studies in this
review is complicated by the use of the sciatic nerve, which possesses a sensory and
motor component, and thus renders functional analysis difficult. It is conceivable for
sensory loss to mask a post-surgical motor defect on gait analysis, similarly, it may be
possible for loss in motor function to cause underestimation of sensory recovery.
Owing to the heterogeneity in starting points for different functional measures, a
pooled analysis  of  quantitative outcomes could not be performed in this review.
Therefore, clinically relevant and robust quantifiable outcome measures remain a
significant  barrier  to  the  reliability  of  animal  studies.  One  study in  this  review
assessed  UCMSC  transplantation  in  human  radial  nerve  defects  and  reported
improved motor and sensory function and electrophysiological  measures[53].  The
group  however,  delivered  the  MSCs  through  a  scaffold,  and  did  not  compare
outcomes with a control group of the scaffold alone.
According to the results of our risk of bias analysis, 13 of 14 studies had a moderate
risk of bias, and one study had a high risk of bias (Figure 1). The reporting of outcome
measures contributed to an increased risk of bias in all studies, as most of the studies
reported improvement in some but not all outcomes yet concluded that UCMSCs
were effective overall. This could be owing to the significant heterogeneity in cell
treatment and delivery methods which as the literature suggests, could contribute to
different aspects of nerve regeneration.
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UCMSCs: Umbilical cord derived mesenchymal stem cells; LOCC: Longitudinally orientated collagen conduit; SFI: Sciatic function index; NGF: Nerve
growth factor; PBS: Phosphate buffered saline; HC: Heparinized collagen; PLC: Poly (DL-lactide-ε-caprolactone); EV: Extracellular vesicle.
In  conclusion,  while  there  are  homeostatic  responses  that  promote  nerve
regeneration following injury,  the  body’s  natural  capacity  is  inadequate  for  the
recovery of satisfactory nerve function. The evidence summarised in this systematic
review supports the notion that UCMSC transplantation is an effective treatment
option for nerve injury. Several barriers must be overcome before these findings can
be translated into the clinical setting. Importantly, development of a reliable in vivo
animal model, and a standardised method of assessing nerve regeneration would
allow the optimal method of cell transplantation to be determined.
ARTICLE HIGHLIGHTS
Research background
Peripheral nerve injury can be a debilitating condition. Traditional treatment options are often
ineffective. There is an urgent need for new treatment modalities. Mesenchymal stem cell (MSC)
transplantation holds promise as a cell-based regenerative approach in treating nerve lesions.
MSCs can be sourced from various tissues, and this may affect their regenerative capacity. Here,
we appraise the in vivo evidence for the use of human umbilical cord-derived MSCs (UCMSCs)
in peripheral nerve regeneration.
Research motivation
There is contention regarding the optimal cell-source for the harvest of MSCs. Some evidence
suggests that MSCs from certain tissue types have superior neurogenic capacity. It is critical that
we determine the best cell-source for nerve repair, in order to facilitate an efficient production
protocol and maximise clinical benefit.
Research objectives
To investigate whether UCMSCs are effective in nerve regeneration in in vivo models of nerve
injury.
Research methods
We performed a systematic literature review according to the PRISMA statement. A search was
conducted on three databases (PubMed, EMBASE and Web of Science) by two independent
investigators from inception to September 2019 for studies examining the use of UCMSCs in in
vivo models of nerve injury. The evidence was appraised using Cochrane’s RoB 2.0 Tool.
Research results
A total  of  14 studies were included in the review, with a total  of  279 subjects.  The studies
reported that transplantation of human umbilical cord MSCs were effective in regenerating
nerve lesions. There were general improvements in histological and functional outcomes. The
studies did not report significant complications.
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Research conclusions
Human umbilical cord-derived MSCs were effective in repairing nerve lesions in both animal
and human models of nerve injury. Additional studies are required to correlate histological
outcomes with functional improvements, as not all studies assessed both. More human studies
are necessary to inform the efficacy in humans. High quality randomized controlled trials would
be instructive in this case. Long-term follow up in these types of study will help inform the
safety of MSC transplantation.
Research perspectives
There is limited evidence examining the use of MSCs derived from other tissues in their capacity
to regenerate nerve lesions. Further studies comparing different tissue cell-source directly would
be highly informative. In vitro studies of MSC-biomaterial scaffolds may aid the development of
more efficient MSC delivery methods. As the nature of nerve injury can vary significantly, the
approach to transplantation, such as dose delivery may need to be catered to the individual
lesion. Studies comparing the effect of MSCs on different in vivo models could help delineate
this.
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